The Magdalen House Opens Men's Program in East Dallas
North Texas Non-Profit Responds to Growing Need for Life-saving Recovery Services
LINK TO HIGH RES PHOTOS
The men's program will begin at
The Magdalen House is committed to help individuals achieve long-term, sustainable recovery through the following spiritually based, comprehensive programs:
- First Step program: A two-week, residential program for an individual with alcoholism who wants to stop drinking but cannot. They are provided with the education and resources to achieve sobriety and build a foundation of recovery.
- Next Step program: A three-phase, nonresidential program for an individual with alcoholism at any stage of recovery. They are provided with structure and education to sustain recovery while growing in knowledge of 12-Step spiritual principles.
- Community: Solution-focused classes, meetings, and workshops are provided for women and men with alcoholism at every stage of recovery, 365 days a year. We also have dedicated volunteers who provide Family Support to families and loved ones of alcoholics.
- Resources and Education: Community partnerships help us connect alcoholic women, men, and their families to resources that include sober living, counseling, and health. At the same time, education initiatives allow us to reach and serve more individuals with alcoholism.
If you're an alcoholic who can't stop drinking or a concerned loved one of an alcoholic, the first step in recovery is education and access to resources. In D/FW, The Magdalen House provides residential recovery, detox, group meetings, structured programs, family support groups, and tools designed to help individuals grow and sustain recovery. For more information please visit, www.magdalenhouse.org.
About The Magdalen House
The
Media Contact:
[email protected]
972,955,9747
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-magdalen-house-opens-mens-program-in-east-dallas-302036557.html
SOURCE The Magdalen House
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
- Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share